High Growth Tech Stocks to Watch in November 2024
In This Article:
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has climbed an impressive 32%, with earnings expected to grow by 15% per annum in the coming years. In this environment of robust growth, identifying high-growth tech stocks that can capitalize on these trends requires a focus on innovation, scalability, and strong financial health.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 23.83% | 24.32% | ★★★★★★ |
| Sarepta Therapeutics | 23.90% | 42.65% | ★★★★★★ |
| Clene | 78.50% | 60.16% | ★★★★★★ |
| TG Therapeutics | 34.66% | 56.48% | ★★★★★★ |
| Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.45% | 70.66% | ★★★★★★ |
| Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
| Blueprint Medicines | 25.47% | 68.62% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
BeiGene
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BeiGene, Ltd. is an oncology-focused company involved in the discovery and development of cancer treatments across the United States, China, Europe, and other international markets with a market capitalization of approximately $20.24 billion.
Operations: BeiGene generates revenue primarily from its pharmaceutical products, amounting to CN¥23.51 billion. The company is focused on oncology, developing treatments for cancer patients across multiple regions.
BeiGene, amidst a challenging landscape marked by a net loss of CNY 3.69 billion for the first nine months of 2024, continues to innovate in the oncology sector with significant advancements in its pipeline. The company’s commitment to research and development is underscored by its recent positive CHMP opinions for TEVIMBRA in various cancer treatments, reflecting a strategic focus on expanding indications which could enhance future revenue streams. Despite these advances and a robust 19.5% year-over-year revenue growth, BeiGene's earnings trajectory faces pressures with an anticipated annual earnings growth rate of 73.2%. This juxtaposition highlights the firm's ongoing investment in transformative cancer therapies while navigating financial volatility inherent in high-stakes biotech endeavors.
-
Click here to discover the nuances of BeiGene with our detailed analytical health report.
-
Understand BeiGene's track record by examining our Past report.
Concentrix
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Concentrix Corporation provides technology-infused customer experience solutions on a global scale and has a market capitalization of approximately $2.83 billion.